- Home
- HOV vs MLYS Comparison
HOV vs MLYS Comparison
Compare HOV & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOV
- MLYS
- Stock Information
- Founded
- HOV 1959
- MLYS 2019
- Country
- HOV United States
- MLYS United States
- Employees
- HOV N/A
- MLYS N/A
- Industry
- HOV Homebuilding
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- HOV Consumer Discretionary
- MLYS Health Care
- Exchange
- HOV Nasdaq
- MLYS Nasdaq
- Market Cap
- HOV 843.6M
- MLYS 893.0M
- IPO Year
- HOV N/A
- MLYS 2023
- Fundamental
- Price
- HOV $96.86
- MLYS $13.90
- Analyst Decision
- HOV Sell
- MLYS Strong Buy
- Analyst Count
- HOV 2
- MLYS 3
- Target Price
- HOV $155.00
- MLYS $33.00
- AVG Volume (30 Days)
- HOV 89.1K
- MLYS 1.2M
- Earning Date
- HOV 05-21-2025
- MLYS 05-08-2025
- Dividend Yield
- HOV N/A
- MLYS N/A
- EPS Growth
- HOV 18.84
- MLYS N/A
- EPS
- HOV 32.36
- MLYS N/A
- Revenue
- HOV $3,084,345,000.00
- MLYS N/A
- Revenue This Year
- HOV N/A
- MLYS N/A
- Revenue Next Year
- HOV $5.54
- MLYS N/A
- P/E Ratio
- HOV $3.14
- MLYS N/A
- Revenue Growth
- HOV 8.80
- MLYS N/A
- 52 Week Low
- HOV $81.15
- MLYS $8.24
- 52 Week High
- HOV $240.34
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- HOV 45.57
- MLYS 50.45
- Support Level
- HOV $90.95
- MLYS $12.77
- Resistance Level
- HOV $105.00
- MLYS $14.14
- Average True Range (ATR)
- HOV 8.48
- MLYS 1.13
- MACD
- HOV 0.76
- MLYS -0.07
- Stochastic Oscillator
- HOV 50.99
- MLYS 68.68
About HOV Hovnanian Enterprises Inc.
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations . The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments; Northeast which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia and West Virginia; Southeast which includes Florida, Georgia and South Carolina; and West which includes Arizona, California and Texas. The firm generates maximum revenue from West Segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.